LENZ Therapeutics Inc banner

Intrinsic Value

Not Available for LENZ

There is not enough data to reliably calculate the intrinsic value for LENZ Therapeutics Inc.

Do our valuations actually work? See backtest results .

Alternatives to LENZ

Fundamental Analysis

What LENZ Therapeutics Does

Pharmaceuticals Health Care

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 152 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia.

Headquarters
United States of America US
Employees
152
IPO date
Jun 25, 2021
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · October 29, 2026

LENZ is reshaping its U.S. commercial model around consumer marketing and telehealth, while announcing a CEO transition as it pursues VIZZ's growth.

Open the earnings call
EPS
−$0.99
Expected
−$0.97
Surprise
−2.1%
Stock, day of the call
+8.7%
View Earnings Call

LENZ Therapeutics insiders are selling within their usual range

Insider trading · Last trade on Oct 29, 2026

Sold $7.3m 1 insider
Bought $365.6k 3 insiders
Trades by date
Open insider trading

Past 12 months

Continue LENZ Research

Decided on LENZ Therapeutics? Get an email when LENZ reaches the price you’d buy at. Free with an account.

Back to Top